Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, sales of Sodium Hyaluronate, focusing on Cosmetics, Medical, Pharmaceutical Grade HA

    Virtual Booth

    Contact Supplier

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    China

    Virtual Booth

    Contact Supplier

    Menu

    1599440-13-7

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Daiichi, Merck pull HER3-DXd filing at FDA
    Daiichi, Merck pull HER3-DXd filing at FDA

    29 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/merck-daiichi-withdraw-us-application-guided-missile-cancer-drug-2025-05-29/

    REUTERS
    29 May 2025
    Share Share
    Alligator Bioscience starts HLX22 Phase 2 trial in breast cancer
    Alligator Bioscience starts HLX22 Phase 2 trial in breast cancer

    23 Apr 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/alligator-bioscience-announces-initiation-of-hlx22-phase-2-trial-in-breast-cancer-by-1018484

    ACCESSWIRE
    23 Apr 2025
    Share Share
    Enhertu drives strong efficacy in first-line breast cancer
    Enhertu drives strong efficacy in first-line breast cancer

    22 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250420186313/en/ENHERTU-Plus-Pertuzumab-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-Versus-THP-as-First-Line-Therapy-for-Patients-with-HER2-Positive-Metastatic-Breast-Cancer

    BUSINESSWIRE
    22 Apr 2025
    Share Share
    ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer
    ENHERTU® Phase 3 Trial Begins for HER2+ Advanced Gastric Cancer

    01 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250328673005/en/DESTINY-Gastric05-Phase-3-Trial-of-ENHERTU-Initiated-in-Patients-with-Previously-Untreated-HER2-Positive-Advanced-Gastric-Cancer

    BUSINESSWIRE
    01 Apr 2025
    Share Share
    Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer
    Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer

    05 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241205215995/en

    BUSINESSWIRE
    05 Dec 2024
    Share Share
    Merck, Daiichi's ADC Lung Cancer Trial Shows Promise Despite Deaths
    Merck, Daiichi's ADC Lung Cancer Trial Shows Promise Despite Deaths

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240917471670/en/Patritumab-Deruxtecan-Demonstrated-Statistically-Significant-Improvement-in-Progression-Free-Survival-Versus-Doublet-Chemotherapy-in-Patients-with-Locally-Advanced-or-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-in-HERTHENA-Lung02-Phase-3-Trial

    BUSINESSWIRE
    18 Sep 2024
    Share Share